Skip to main content

Advertisement

SpringerLink
Log in

Advances in Diagnosis and Treatment of Interstitial Cystitis/Painful Bladder Syndrome

  • Genitourinary Infections (J Sobel, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a prevalent chronic condition that can be challenging not only to diagnose but also to treat. We review recent diagnostic markers and therapies for IC/BPS from non-medication-based therapies, oral therapies, intravesical therapies, and surgical treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Parson JK, Parsons CL. The historical origins of interstitial cystitis. J Urol. 2004;171:20–2.

    Google Scholar 

  2. Skene AJC. Disease of the bladder and urethra in women. New York: Wm Wood; 1887. p. 167.

    Google Scholar 

  3. Hunner GL. A rare type of bladder ulcer in women: report of cases. Boston Med Surg J. 1915;172:660–4.

    Google Scholar 

  4. Hand JR. Interstitial cystitis: report of 223 cases (204 women and 19 men). J Urol. 1949;61:291–309.

    CAS  PubMed  Google Scholar 

  5. Chrysanthopoulou EL, Doumouchtsis SK. Challenges and current evidence on the management of bladder pain syndrome. Neurourol Urodyn. 2013. doi:10.1002/nau.22475. Provides current evidence on the management of IC/BPS and provides definitions of IC/BPS according to different organization.

    PubMed  Google Scholar 

  6. Hanno PM, Allen D, Burks JQ, Roger C, et al. AUA guidelines for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185:2162–70. AUA guidelines provide overall management strategy for IC/BPS based upon a systematic review of the literature.

    PubMed  Google Scholar 

  7. Hanno P, Dmochowski R. Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn. 2009;28:274.

    PubMed  Google Scholar 

  8. Braunstein R, Shapiro K, Kaye J, et al. The role of cystoscopy in the diagnosis of Hunner’s ulcer disease. J Urol. 2008;180:1383–6.

    PubMed  Google Scholar 

  9. Koziol JA, Adams HP, Frutas A. Discrimination between the ulcerous and the nonulcerous forms of interstitial cystitis by non-invasive findings. J Urol. 1996;155:87–90.

    CAS  PubMed  Google Scholar 

  10. Tomaszewski JE, Landi JR, Russack V, et al. Biopsy features are associated with primary symptoms in interstitial cystitis: results from the interstitial cystitis database study. Urology. 2001;57:67–81.

    CAS  PubMed  Google Scholar 

  11. Peeker R, Fall M. Toward a precise definition of interstitial cystitis: further evidence of differences in classic and nonulcer disease. J Urol. 2002;167:2470–2.

    PubMed  Google Scholar 

  12. Peeker R, Aldenborg F, Fall M. The treatment of interstitial cystitis with supratrigonal cystectomy and ileocystoplasty: difference in outcome between classic and nonulcer disease. J Urol. 1998;159:1479–82.

    CAS  PubMed  Google Scholar 

  13. Warren JW, Wesselmann U, Morozov V, et al. Numbers and types of nonbladder syndromes as risk factors for interstitial cystitis/painful bladder syndrome. Urology. 2011;77:313–9.

    PubMed  Google Scholar 

  14. Clemens JQ, Meenan RT, O’Keefe-Rosetti MC, et al. Case-control study of medical comorbidities in women with interstitial cystitis. J Urol. 2008;179:2222–5.

    PubMed  Google Scholar 

  15. Rodriguez MA, Afari N, Buchwald DS. Evidence for overlap between urological and nonurological unexplained clinical conditions. J Urol. 2013;189:S66–74.

    Google Scholar 

  16. Warren JW, van de Merwe JP, Nickel JC. Interstitial cystitis/bladder pain syndrome and nonbladder syndromes: facts and hypotheses. Urology. 2011;78:727–32.

    PubMed  Google Scholar 

  17. Chelimsky G, Heller E, Buffington CA, et al. Co-morbidities of interstitial cystitis. Front Neurosci. 2012;6:114.

    PubMed Central  PubMed  Google Scholar 

  18. Lifford KL, Curhan GC. Prevalence of painful bladder syndrome in older women. J Urol. 2008;73:494.

    Google Scholar 

  19. Rosenberg MT, Hazzard M. Prevalence of interstitial cystitis symptoms in women: a population based study in the primary care office. J Urol. 2005;174:2231–4.

    PubMed  Google Scholar 

  20. Clemens JQ, Meenan RT, O’Keefe, et al. Prevalence of interstitial cystitis symptoms in a managed care population. J Urol. 2005;174:576–80.

    PubMed  Google Scholar 

  21. Hanno PM. Chapter 12: bladder pain syndrome (interstitial cystitis) and related disorders. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters AC, editors. Campbell-Walsh urology. 10th ed. Philadelphia: Saunders/Elsevier; 2011. p. 357–401.

    Google Scholar 

  22. Berry SH, Elliott MN, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186:540–4.

    PubMed Central  PubMed  Google Scholar 

  23. Warren JW, Langenberg P, Greenberg P, et al. Sites of pain from interstitial cystitis/painful bladder syndrome. J Urol. 2008;180:1373–7.

    PubMed  Google Scholar 

  24. Tripp DA, Nickel JC, Wong J, et al. Mapping of pain phenotypes in female patients with bladder pain syndrome/interstitial cystitis and controls. Eur Urol. 2012;62:1188–94.

    PubMed  Google Scholar 

  25. Van De Merwe J, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53:60–7. Important paper on how to properly use the term IC/BPS.

    PubMed  Google Scholar 

  26. Peters KM, Killinger KA, Carrico DJ, et al. Sexual function and sexual distress in women with interstitial cystitis: a case-control study. Urology. 2007;70:543–7.

    PubMed  Google Scholar 

  27. Cole EE, Scarpero HM, Dmochowski RR. Are patient symptoms predictive of the diagnostic and/or therapeutic value of hydrodistention? Neurourol Urodyn. 2005;24:638–42.

    PubMed  Google Scholar 

  28. Richter B, Hesse U, Hansen AB, et al. Bladder pain syndrome/interstitial cystitis in a Danish population: a study using the 2008 criteria of the European society for the study of interstitial cystitis. BJU Int. 2010;105:660–7.

    PubMed  Google Scholar 

  29. Keay S, Zhang C-O, Chai T, Warren J, Koch K, Grkovic D, et al. Antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor in men with interstitial cystitis vs. chronic pelvic pain syndrome. Urology. 2004;63:22–6.

    PubMed  Google Scholar 

  30. Erickson DR, Kunselman AR, Bentley CM, et al. Changes in urine markers and symptoms after bladder distention for interstitial cystitis. J Urol. 2007;177:556–60.

    PubMed Central  PubMed  Google Scholar 

  31. Chung SD, Liu HT, Lin H, et al. Elevation of serum C-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder. Neurourol Urodyn. 2011;30:417–20.

    CAS  PubMed  Google Scholar 

  32. Kuo HC, Liu H, Tyagi P, Chancellor MB. Urinary nerve growth factor levels in urinary tract diseases with or without frequency urgency symptoms. LUTS. 2010;2:88–94.

    CAS  Google Scholar 

  33. Kuo HC. Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis. Int J Urol. 2014;21(1):34–41. Review of urine and serum biomarkers for IC/BPS.

    PubMed  Google Scholar 

  34. Tyagi P, Killinger K, Tyagi V, et al. Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. J Urol. 2012;187:2243–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  35. Cervigni M, Natale F, Nasta L, Padoa A, Voi R, Porru D. A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:943–7.

    CAS  PubMed  Google Scholar 

  36. Giannantoni A, Bini V, Dmochowski R, et al. Contemporary management of the painful bladder: a systematic review. Eur Urol. 2012;61:29–53.

    PubMed  Google Scholar 

  37. Shorter B, Lesser M, Moldwin R, et al. Effect of comestibles on symptoms of interstitial cystitis. J Urol. 2007;178:145–52.

    PubMed  Google Scholar 

  38. Fisher BP, Bavendam TG, Roberts BW, et al. Blinded placebo controlled evaluation on the ingestion of acidic foods and their effect on urinary pH and the symptomatology of interstitial cystitis. Orlando: FL, NIDDK; 1993. p. 53.

    Google Scholar 

  39. Bassaly R, Downes K, Hart S. Dietary consumption triggers in interstitial cystitis/bladder pain syndrome. Female Pelvic Med Reconstr Surg. 2011;17(1):36–9.

    PubMed  Google Scholar 

  40. Peters DM, Carrico DJ, Kalinowski SE, et al. Prevalence of pelvic floor dysfunction in patients with interstitial cystitis. Urology. 2007;70:16.

    PubMed  Google Scholar 

  41. Simons DG, Travell JG, Simons LS. Travell and Simons myofascial pain and dysfunction: the trigger point manual, vol. 1. 2nd ed. Baltimore: Williams & Wilkins; 1999.

    Google Scholar 

  42. Fitzgerald MP, Anderson RU, Potts J, et al. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol. 2009;182:570.

    PubMed Central  PubMed  Google Scholar 

  43. Weiss JM. Pelvic floor myofascial trigger points: manual therapy for interstitial cystitis and the urgency-frequency syndrome. J Urol. 2001;166:2226–31.

    CAS  PubMed  Google Scholar 

  44. Oyama IA, Rejba A, Lukban JC, et al. Modified Thiele massage as therapeutic intervention for female patients with interstitial cystitis and high-tone pelvic floor dysfunction. Urology. 2004;64:862.

    PubMed  Google Scholar 

  45. Fitzgerald MP, Payne CK, Lukacz ES, et al. Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor tenderness. J Urol. 2012;187:2113–8. Demonstrated efficacy of myofascial physical therapy compared to therapeutic massage in relieving IC/BPS.

    PubMed Central  CAS  PubMed  Google Scholar 

  46. Van Ophoven A, Pokupic S, Heinecke A, et al. A prospective, randomized, placebo controlled, double blind study of amitriptyline for the treatment of interstitial cystitis. J Urol. 2004;172:533.

    PubMed  Google Scholar 

  47. Foster Jr HE, Hanno PM, Nickel JC, et al. Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010;183:1853–8.

    PubMed Central  PubMed  Google Scholar 

  48. Lee JW, Han DY, Jeong HJ. Bladder pain syndrome treated with triple therapy with gabapentin, amitriptyline, and a nonsteroidal anti-inflammatory drug. Int Neurourol J. 2010;14:256–60.

    PubMed Central  PubMed  Google Scholar 

  49. Kwon WA, Ahn SH, Oh TA. Effect of low-dose triple therapy using gabapentin, amitriptyline, and a nonsteroidal anti-inflammatory drug for overactive bladder symptoms in patients with bladder pain syndrome. Int Neurourol J. 2013;17:78–82.

    PubMed Central  PubMed  Google Scholar 

  50. Thilagarajah R, Witherow RO, Walker MM. Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. BJU Int. 2001;87:207–12.

    CAS  PubMed  Google Scholar 

  51. Seshadri P, Emerson L, Moarles A. Cimetidine in the treatment of interstitial cystitis. Urology. 1994;44:614–6.

    CAS  PubMed  Google Scholar 

  52. Dasgupta P, Sharma SD, Womack C, et al. Cimetidine in painful bladder syndrome: a histopathological study. BJU Int. 2001;88:183–6.

    CAS  PubMed  Google Scholar 

  53. Davis EL, El Khoudary SR, Talbott EO, et al. Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. J Urol. 2008;179(1):177–85.

    CAS  PubMed  Google Scholar 

  54. Nickel JC, Barkin J, Forrest J, et al. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology. 2005;65:654–8.

    PubMed  Google Scholar 

  55. Sant GR, Propert KJ, Hanno PM, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003;170:810–5.

    CAS  PubMed  Google Scholar 

  56. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Effectiveness and safety study of pentosan polysulfate sodium for the treatment of interstitial cystitis. http://clinicaltrials.gov/show/NCT00086684.

  57. Minogiannis P, El-Mansoury M, Betances JA, et al. Hydroxyzine inhibits neurogenic bladder mast cell activation. Int J Immunopharmacol. 1998;20:553–63.

    CAS  PubMed  Google Scholar 

  58. Theoharides TC. Hydroxyzine in the treatment of interstitial cystitis. Urol Clin N Am. 1994;21:113–9.

    CAS  Google Scholar 

  59. Theoharides TC, Sant GR. Hydroxyzine therapy for interstitial cystitis. Urology. 1997;49:108.

    CAS  PubMed  Google Scholar 

  60. Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol. 2004;171:2138–41.

    CAS  PubMed  Google Scholar 

  61. Sairanen J, Tammela TL, Leppilahti M, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol. 2005;174:2235–8.

    CAS  PubMed  Google Scholar 

  62. Forrest JB, Payne CK, Erickson DR. Cyclosporin A for refractory interstitial cystitis/bladder pain syndrome: experience of 3 tertiary centers. J Urol. 2012;188(4):1186–91.

    CAS  PubMed  Google Scholar 

  63. Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci. 2006;27:85.

    CAS  PubMed  Google Scholar 

  64. Delafoy L, Taymond F, Doherty AM, et al. Role of nerve growth factor in the trinitrobenzene sulfonic acid-induced colonic hypersensitivity. Pain. 2003;105:489.

    CAS  PubMed  Google Scholar 

  65. Lamb K, Kang YM, Gebhart GF, et al. Nerve growth factor and gastric hyperplasia in the rat. Neurogastroenterol Motil. 2003;15:355.

    CAS  PubMed  Google Scholar 

  66. Evans RJ, Moldwin RM, Cossons N, et al. Proof of concept trail of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011;185(5):1716–21. Randomized, double blind study showing efficacy of tanezumab.

    CAS  PubMed  Google Scholar 

  67. Teichman JM, Moldwin R. The role of the bladder surface in interstitial cystitis/painful bladder syndrome. Can J Urol. 2007;4:3599–607.

    Google Scholar 

  68. Parsons CL. The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology. 2007;69:9–16.

    PubMed  Google Scholar 

  69. Parsons CL, Housley T, Schmidt JD, et al. Treatment of interstitial cystitis with intravesical heparin. Br J Urol. 1994;73:504–7.

    CAS  PubMed  Google Scholar 

  70. Henry R, Patterson L, Avery N, et al. Absorption of alkalized intravesical lidocaine in normal and inflamed bladders: a simple method for improving bladder anesthesia. J Urol. 2001;165:1900–3.

    CAS  PubMed  Google Scholar 

  71. Parsons CL. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology. 2005;65(1):45–8.

    PubMed  Google Scholar 

  72. Welk BK, Teichman JM. Dyspareunia response in patients with interstitial cystitis treated with intravesical lidocaine, bicarbonate, and heparin. Urology. 2008;71(1):67–70.

    PubMed  Google Scholar 

  73. Nomiya A, Naruse T, Niimi A, et al. On- and post-treatment symptom relief by repeated instillations of heparin and alkalized lidocaine in interstitial cystitis. Int J Urol. 2013;20:1118–22.

    CAS  PubMed  Google Scholar 

  74. Nickel JC, Egerdie RB, Steinhoff G, et al. A multi-center, randomized, double-blind, parallel group pilot evaluation of the efficacy and safety of intravesical sodium chondroitin sulfate versus vehicle control in patients with interstitial cystitis/painful bladder syndrome. Urol. 2010;76:804–9.

    PubMed  Google Scholar 

  75. Nickel JC, Hanno P, Kumar K, et al. Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. Urology. 2012;79:1220–4.

    PubMed  Google Scholar 

  76. Thakkinstian A, Nickel JC. Efficacy of intravesical chondroitin sulphate in treatment of interstitial cystitis/bladder pain syndrome (IC/BPS): individual patient data (IPD) meta-analytical approach.

  77. Engelhardt PF, Morakis N, Daha LK, et al. Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2011;22:401–5.

    PubMed  Google Scholar 

  78. Interstitial Cystitis Association. Bioniche trial. 2003.

  79. Reece JB, Urry L, Cain M, et al. Campbell biology (9th edition; international edition.). Harlow: Pearson Education; 2011.

    Google Scholar 

  80. Nickel JC et al. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009;103:910–8. The major study in demonstrating the efficacy of intravesicular lidocaine.

    CAS  PubMed  Google Scholar 

  81. Nickel JC, Jain P, Shore N, et al. Continuous intravesical lidocaine treatment for interstitial cystitis / bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med. 2012;4:143ra100.

    PubMed  Google Scholar 

  82. Nickel JC. Placebo controlled study of safety, tolerability, and efficacy of LiRIS in women with interstitial cystitis, followed by open label extension. IN: ClinicalTrails.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT01475253. Cited 2014 Aug.

  83. Lv YS, Zhou HL, Mao HP, et al. Intravesical hyaluronic acid, alkalinized lidocaine for the treatment of severe painful bladder syndrome/interstitial cystitis. Int Urogynecol J. 2012;23:1715–20.

    PubMed  Google Scholar 

  84. Jacob SW, Bischel M, Herschler RJ. Dimethyl sulfoxide (DMSO): a new concept in pharmacotherapy. Curr Ther Res. 1964;6:134–5.

    CAS  PubMed  Google Scholar 

  85. Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol. 1988;140:36–9.

    CAS  PubMed  Google Scholar 

  86. Peeker R, Haghsheno MA, Holmang S, et al. Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: a prospective, randomized double blind study. J Urol. 2000;164:1912–5.

    CAS  PubMed  Google Scholar 

  87. Stav K, Beberashvili I, Lindner A, et al. Predictors of response to intravesical dimethyl-sulfoxide cocktail in patients with interstitial cystitis. Urology. 2012;80:61–5.

    PubMed  Google Scholar 

  88. Hung MJ, Chet YT, Shen PS, et al. Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail. Int Urogynecol J. 2012;23(11):1533–9.

    PubMed  Google Scholar 

  89. Chuang YC, Tyagi P, Hunag CC, et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol. 2009;182:786–92.

    CAS  PubMed  Google Scholar 

  90. Fraser MO, Chuang YC, Tyagi P, et al. Intravesical liposomes administration: a novel treatment for hyperactive bladder in the rat. Urology. 2003;61:656–63.

    PubMed  Google Scholar 

  91. Chuang YC, Lee WC, Chiang PH. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol. 2009;182:1393–400.

    CAS  PubMed  Google Scholar 

  92. Lee WC, Chuang YC, Lee WC, et al. Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome. Kaohsiung J Med Sci. 2011;27:437–40.

    CAS  PubMed  Google Scholar 

  93. Kaufman J, Lipella Pharmaceuticals Inc. Efficacy of Intravesical LP08 in patients with interstitial cystitis/painful bladder syndrome. IN: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: http://clinicaltrials.gov/show/NCT01393223. NCT identifier: 01393223. Cited 2014 Aug.

  94. Cruz F. Targets for botulinum toxin in the lower urinary tract. Neurourol Urodyn. 2014;33:31–8.

    CAS  PubMed  Google Scholar 

  95. Rapp DE, Turk KW, Bales GT, et al. Botolinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol. 2006;175:1138–42.

    CAS  PubMed  Google Scholar 

  96. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009;1:1–5.

    Google Scholar 

  97. Kuo HC. Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome. Pain Physician. 2013;16(1):15–23.

    Google Scholar 

  98. Pinto R, Lopes T, Silva J, et al. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis. J Urol. 2013;189:548–53.

    CAS  PubMed  Google Scholar 

  99. Manning J, Dywer P, Rosamilia A, et al. A multicentre, prospective, randomized, double-blind study to measure the treatment effectiveness of abobotulinum A (AboBTXA) among women with refractory interstitial cystitis/bladder pain syndrome. Int Urogynecol J. 2014;25:593–9.

    PubMed  Google Scholar 

  100. Ottem DP, Teichman JM. What is the value of cystoscopy with hydrodistention for interstitial cystitis? Urology. 2005;66:494–9.

    PubMed  Google Scholar 

  101. Hillelsohn JH, Rais-Bahrami S, Friedlander JI, et al. Fulguration for Hunner ulcers: long-term clinical outcomes. J Urol. 2012;188(6):2238–41.

    PubMed  Google Scholar 

  102. Roffiem O, Hom D, Freid RM, et al. Use of the neodymium:YAG laser for interstitial cystitis: a prospective study. J Urol. 2001;166(1):134–6.

    Google Scholar 

  103. Cox M, Klutke JJ, Klutke CG. Assessment of patient outcomes following submucosal injection of triamcinolone for treatment of Hunner’s ulcer subtype interstitial cystitis. Can J Urol. 2009;16(2):4536–40.

    PubMed  Google Scholar 

  104. Weiss JP, Mattei DM, Neville EC, et al. Primary treatment of radiation-induced hemorrhagic cystitis with hyperbaric oxygen: 10-year experience. J Urol. 1994;151(6):1514–7.

    CAS  PubMed  Google Scholar 

  105. Hader JE, Marzella L, Myers RA, et al. Hyperbaric oxygen treatment for experimental cyclophosphamide-induced hemorrhagic cystitis. J Urol. 1993;149(6):1617–21.

    CAS  PubMed  Google Scholar 

  106. Tanaka T, Nitta Y, Morimoto K, et al. Hyperbaric oxygen therapy for painful bladder syndrome/interstitial cystitis resistant to conventional treatments: long-term results of a case series in Japan. BMC Urol. 2011;11:11.

    PubMed Central  CAS  PubMed  Google Scholar 

  107. Gallego-Vilar D, Garcia-Fadrique G, Povo-Martin I, et al. Maintenance of the response to dimethyl sulfoxide treatment using hyperbaric oxygen in interstitial cystitis/painful bladder syndrome: a prospective, randomized, comparative study. Urol Int. 2013;9:411–6.

    Google Scholar 

  108. Shaker H, Wang Y, Loung D, et al. Role of C-afferent fibres in the mechanism of action of sacral nerve root neuromodulation in the chronic spinal cord injury. BJU Int. 2000;85:905–10.

    CAS  PubMed  Google Scholar 

  109. Gajewski JM, Al-Zahrani AA. The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre. BJU Int. 2011;107(8):1258–64.

    PubMed  Google Scholar 

  110. Ghazwani YQ, Elkelini MS, Hassouna MM. Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up. Neurourol Urodyn. 2011;30(7):1271–5. Summarizes the experience of neuromodulation for pain in IC/BPS.

    PubMed  Google Scholar 

  111. Peters KM, Fever KM, Bennett RC. A prospective, single-blind, randomized crossover trial of sacral vs pudendal nerve stimulation for interstitial cystitis. BJU Int. 2007;100:835–9.

    PubMed  Google Scholar 

  112. Gokyildiz S, Kizilkaya Beji N, Yalcin O, et al. Effects of percutaneous tibial nerve stimulation therapy on chronic pelvic pain. Gynecol Obstet Investig. 2012;73(2):99–105.

    Google Scholar 

  113. Peters KM, Jaeger C, Killinger KA, et al. Cystectomy for ulcerative interstitial cystitis: sequelae and patients’ perceptions of improvement. J Urol. 2013;82:829–33.

    Google Scholar 

  114. Rossberger J, Fall M, Jonsson O, et al. Long-term results of reconstructive surgery in patients with bladder pain syndrome/interstitial cystitis: subtyping is imperative. Urology. 2007;70:638.

    PubMed  Google Scholar 

  115. Elliott CS, Payne CK. Interstitial cystitis and the overlap with overactive bladder. Curr Urol Rep. 2012;13(5):319–26.

    PubMed  Google Scholar 

Download references

Acknowledgments

Support from the Ministrelli Program for Urology Research and Education—MPURE is gratefully acknowledged.

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Avinash Chennamsetty, Kim Killinger, Michael Ehlert, and Kenneth Peters have no conflicts of interest relevant to this work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Department of Urology, Beaumont Health System, 3535 W. 13 Mile Rd., Ste. 438, Royal Oak, MI, 48073, USA

    Avinash Chennamsetty, Michael J. Ehlert, Kenneth M. Peters & Kim A. Killinger

  2. Oakland University William Beaumont School of Medicine, Rochester, MI, 48309, USA

    Kenneth M. Peters

Authors
  1. Avinash Chennamsetty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J. Ehlert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenneth M. Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kim A. Killinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Avinash Chennamsetty.

Additional information

This article is part of the Topical Collection on Genitourinary Infections

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chennamsetty, A., Ehlert, M.J., Peters, K.M. et al. Advances in Diagnosis and Treatment of Interstitial Cystitis/Painful Bladder Syndrome. Curr Infect Dis Rep 17, 454 (2015). https://doi.org/10.1007/s11908-014-0454-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11908-014-0454-5

Keywords

Search

Navigation